Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 7/7/2020
SIETES contiene 93061 citas

 
 
 1 a 20 de 73 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Yang M-S, Lee JY, Kim J, Kim G-W, Kim B-K, Kim Y, Park H-W, Cho S-H, Min K-U, Kang H-R. Searching for the culprit drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis from a nationwide claim database in Korea. J Allergy Clin Immunol 2020;8:febrero. [Ref.ID 103535]
2. Cita con resumen
Sys J, Van Cleynenbreugel S, Deschodt M, Van der Linden L, Tournoy J. Efficacy and safety of non-benzodiazepine and non-Z-drug hypnotic medication for insomnia in older people: a systematic literature review. Eur J Clin Pharmacol 2020;76:marzo. [Ref.ID 103530]
3. Cita con resumen
Azzouz B, Morel A, Kanagaratman L, Herlem E, Trenque T. Psoriasis after exposure to angiotensin-converting enzyme inhibitors: French pharmacovigilance data and review of the literature. Drug Saf 2019;42:diciembre. [Ref.ID 103209]
4.Enlace a cita original Cita con resumen
Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression — First FDA-approved antidepressant in a new class. N Engl J Med 2019;381:4 de julio. [Ref.ID 103124]
5.Enlace a cita original Cita con resumen
Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium–glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med 2019:7 de mayo. [Ref.ID 103108]
7.Enlace a cita original Cita con resumen
Bouvy JC, Huinink L, De Bruin ML. Benefit-risk reassessment of medicines: a retrospective analysis of all safety-related referral procedures in Europe during 2001–2012. Pharmacoepidemiol Drug Saf 2016;25:1004-14. [Ref.ID 100902]
9. Cita con resumen
de Maleissye M-F, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med 2016;375:296-7. [Ref.ID 100503]
10. Cita con resumen
Greene MF, Drazen JM. A new label for mifepristone. N Engl J Med 2016;374:2281-2. [Ref.ID 100400]
12. Cita con resumen
Ferro A. Newer antiplatelet agents in acute coronary syndrome. BMJ 2016;352:h7025. [Ref.ID 99965]
13. Cita con resumen
Anónimo. Rivaroxaban: atteintes hépatiques. Prescrire 2015;35:432. [Ref.ID 99428]
14. Cita con resumen
Anónimo. Traitements des cancers de l'enfance: effets indésirables à long terme. Prescrire 2015;35:348-52. [Ref.ID 99136]
15. Cita con resumen
Anónimo. Voriconazole: alopécies et modifications des ongles. Prescrire 2014;34:749. [Ref.ID 98263]
16. Cita con resumen
Hue TF, Cummings SR, Cauley JA, Bauer DC, Ensrud KE, Barrett-Connor E, Black DM. Effect of bisphosphonate use on risk of postmenopausal breast cancer. Results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med 2014;174:1550-7. [Ref.ID 97886]
17. Cita con resumen
Anónimo. Atazanavir: lithiases urinaires. Prescrire 2014;34:266. [Ref.ID 97440]
19. Cita con resumen
Smith RM, Tipple M, Chaudry MN, Schaefer MK, Park BJ. Relapse of fungal meningitis associated with contaminated methylprednisolone. N Engl J Med 2013;368:1. [Ref.ID 95554]
20. Cita con resumen
Feely MA, Mabry TM, Lohse CM, Sems SA, Mauck KF. Safety of clopidogrel in hip fracture surgery. Mayo Clin Proc 2013;88:149-56. [Ref.ID 95136]
Seleccionar todas
 
 1 a 20 de 73 siguiente >>